Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
102 hedge funds and large institutions have $182M invested in Eiger BioPharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 44 increasing their positions, 24 reducing their positions, and 9 closing their positions.
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
83% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 24
9% more funds holding
Funds holding: 94 → 102 (+8)
3% less capital invested
Capital invested by funds: $187M → $182M (-$5.26M)
46% less call options, than puts
Call options by funds: $1.09M | Put options by funds: $2.03M
67% less funds holding in top 10
Funds holding in top 10: 6 → 2 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$14.4M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.07M |
| 3 |
6CM
683 Capital Management
New York
|
+$4.83M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.53M |
| 5 |
BlackRock
New York
|
+$2.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.81M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.6M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.59M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.53M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.26M |
EIGR Hedge Fund Activity: Q3 2020 in Review
102 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q3 2020, worth a combined $182M — down 2.8% from $187M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new EIGR positions and 9 closed out — a net gain of 8 holders — while 44 added to existing stakes and 24 trimmed.
The largest buyer was Ameriprise, opening a new position worth an estimated $14.4M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $2.81M sold.
- 102 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q3 2020, up from 94 in Q2 2020.
- Funds reported $182M of Eiger BioPharmaceuticals, Inc. stock for Q3 2020, down 2.8% quarter-over-quarter.
- 17 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q3 2020 and 9 closed out, a net change of +8 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q3 2020 was Ameriprise, an estimated $14.4M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q3 2020 was Acuta Capital Partners, an estimated $2.81M sold.
Based on aggregated 13F filings for Q3 2020.